CXCL1 and fibrosis: Similarly, lung inflammatory cytokine levels of CXCL1, TNF-α, and MPO were significantly decreased by G31P alone or in combination with gefitinib compared to the fibrosis control (p < 0.05), while no significant difference was observed between the gefitinib and fibrosis control groups (Fig. 5F,G).